Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR58611A vs placebo for prevention of relapse in major depressive disorder
2005-004006-81Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amibegron in major depressive disorder (MDD) (3 arms), sponsored by Sanofi. Primary endpoint: Time to relapse / recurrence of depressive disorder. Started Feb 2006; status: completed.
02
Drugs
amibegron
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2005-004006-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004006-81.